Glenmark Pharmaceuticals Limited — Updates, 06-11-2024: Press Release

Ichnos Glenmark Innovation (IGI) announced the first presentation of data from a Phase 1 study of its trispecific antibody, ISB 2001, targeting relapsed/refractory multiple myeloma (r/r MM), demonstrating a 75% overall response rate and favorable safety profile. At the upcoming ASH Annual Meeting, IGI will also present data on another candidate, ISB 1442. The studies showcase IGI's commitment to advancing innovative therapies for challenging cancer types.